Methods for identifying novel therapeutics and diagnostics in the p53 pathway
View Patent ↗The present invention identifies a p53 homolog gene, cep-1, and mutations thereof in the nematode C. elegans which allows for the application of molecular genetic methods to identify new components of the p53 pathway as well as genes that act in parallel to the p53 pathway. cep-1 mutants show elevated physiological germ cell death during normal development. The present invention also provides a simple system with which to perform high-throughput screens for pharmacological agents that suppress the effects of eliminating the cep-1 gene or that enhance its effectiveness when in a mutant state. This strategy should identify agents that selectively kill p53-deficient cells that are resistant to traditional chemotherapeutic regimens and thus block the formation of human tumors that arise when p53 function is compromised.
1. A Cuenorhabditis elegans ( C. elegans ) knockout mutant, said mutant comprising a structural or functional deletion of the wild-type cep-1 gene and having a phenotype of one or more features selected from the group consisting of increased resistance to ionizing radiation-induced programmed cell death, increased life span after exposure to ionizing radiation, increased sensitivity to oxygen deprivation, increased sensitivity to starvation, reduced life span after diapause arrest, abnormally small size, uncoordinated movement, and elevated levels of programmed cell death in the germline.
2. The C. elegans knockout mutant of claim 1 , comprising a chromosomal deletion of one or more domains of the cep-1 gene selected from the group consisting of exons II, III, and IV.
3. The C. elegans knockout mutant of claim 1 , comprising a functional deletion of the cep-1 gene produced by RNA-mediated interference (RNAi).
4. The C. elegans knockout mutant of claim 1 , which knockout mutant is a homozygous knockout mutant.
5. A C. elegans transgenic nematode comprising a gene construct stably integrated into the genome of said nematode, wherein said gene construct comprises a heterologous nucleic acid wherein the heterologous nucleic acid is operably linked to an inducible promoter, and wherein the heterologous nucleic acid is a nucleic acid encoding SEQ ID NO: 1 or fragment thereof that is at least 95% identical to SEQ ID NO: 1 and which has anti-apoptotic activity and wherein said nematode exhibits increased lethality upon expression of protein encoded by said heterologous nucleic acid at a larval or adult stage.
6. The transgenic nematode of claim 5 , wherein said heterologous nucleic acid is a wild-type C. elegans cep-1 gene.
7. The transgenic nematode of claim 5 , wherein said protein encoded by said heterologous nucleic acid comprises a mutant form of a mutant form of SEQ ID NO: 1 that is at least 95% identical to SEQ ID NO: 1 and which has anti-apoptotic activity.
8. The transgenic nematode of claim 5 , wherein said heterologous nucleic acid is operably linked to a nematode hsp16 promoter.
9. A kit comprising:
a test chamber containing liquid growth medium and a Caenorhabditis elegans knockout mutant, said mutant comprising a structural or functional deletion of the wild-type cep-1 gene and having a phenotype of one or more features selected from the group consisting of increased resistance to ionizing radiation-induced programmed cell death, increased life span after exposure to ionizing radiation, increased sensitivity to oxygen deprivation, increased sensitivity to starvation, reduced life span after diapause arrest, abnormally small size, uncoordinated movement, and elevated levels of programmed cell death in the germline.